Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration
... the symptoms of Attention-Deficit/Hyperactivity
disorder (ADHD) in children aged 6 to 12 from the first ... for Disease Control and Prevention (CDC). The
disorder is also estimated to affect 4.4 percent of US ... ADHD.
ADHD is a psychiatric behavioral
disorder that manifests as a persistent pattern of ...
Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
... acute and preventative treatment of the bleeding
disorder associated with hemophilia B. IB1001 is produced ...
Hemophilia is a lifelong, inherited bleeding
disorder caused by low levels or absence of a protein ... to develop a portfolio of hemophilia and bleeding
disorder products that address a $7 billion market ...
REMERON(R) Now Approved in Japan for the Treatment of Depression in Adult Patients
... indicated for the treatment of major depressive
disorder (MDD) in adults. REMERONSolTab(R) is not approved ... adults in short-term studies of major depressive
disorder (MDD) and other psychiatric disorders. Anyone ... and Suicide Risk
Patients with major depressive
disorder (MDD), both adult and pediatric, may experience ...
Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
... in adults with Attention Deficit Hyperactivity
disorder (ADHD). VYVANSE is the first approved stimulant ... for Disease Control and Prevention (CDC). The
disorder is also estimated to affect 4.4 percent of US ... have ADHD.
ADHD is a psychiatric behavioral
disorder that manifests as a persistent pattern of ...
FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD
... its once-daily Attention Deficit Hyperactivity
disorder (ADHD) treatment VYVANSE (R) (lisdexamfetamine ... for Disease Control and Prevention (CDC). The
disorder is also estimated to affect 4.4 percent of US ... ADHD.
ADHD is a psychiatric behavioral
disorder that manifests as a persistent pattern of ...
ViroPharma Incorporated Honored by the National Organization for Rare Disorders
... (human)) to market for a rare and devastating
disorder -- hereditary angioedema (HAE).
HAE is a rare, severely debilitating, life-threatening genetic
disorder caused by a deficiency of C1 inhibitor, a human ... severely debilitating, life-threatening genetic
disorder caused by a deficiency of C1 inhibitor, a human ...
BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA
... for the treatment of the lysosomal storage
disorder Mucopolysaccharidosis Type IVA (MPS IVA), or ... will aid in our scientific understanding of the
disorder as we further pursue this program."
The ... (MPS IVA, also known as Morquio A Syndrome) is a
disorder characterized by deficient activity of ...
Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
... the treatment of Attention Deficit
Hyperactivity
disorder (ADHD).
EQUASYM XL is approved and ... for Disease Control and
Prevention (CDC). The
disorder is also estimated to affect 4.4 percent of ...
ADHD is a psychiatric behavioral
disorder that manifests as a persistent
pattern of ...
FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder
... of mood episodes in patients with bipolar
disorder who relapsed frequently.
The Agency's ... resolve any outstanding questions.
Bipolar
disorder is a brain
disorder that causes unusual shifts in a person's mood, ...
Shire's New Product Portfolio Delivers Strong Quarterly Performance
... dimesylate) - Attention Deficit and
Hyperactivity
disorder ("ADHD")
- The launch of VYVANSE for adult ... treatment of MLD, which is a lysosomal storage
disorder that results from a deficiency in the enzyme ... its business on attention deficit
hyperactivity
disorder (ADHD), human genetic therapies (HGT) ...
From Pain to Unexpected Fame: One Woman's Journey to Know Fibro
... for 20 years, and when
patients learn about the
disorder and what types of things they can do
themselves ... Fibromyalgia
Fibromyalgia is a chronic pain
disorder estimated to affect 2 percent
of the U.S. ... and
understands the challenges those with the
disorder face. She has a
bachelor's, a master's and a ....
FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
... and the maintenance treatment of bipolar I
disorder as adjunctive
therapy to lithium or divalproex. ... disorder.(1)
"When people think about bipolar
disorder it is important to remember
how debilitating the ... In fact, in
the long term, patients with bipolar
disorder experience depressive
symptoms three times longer ...
Celebrity Designer Ty Pennington to Host 10th Annual 'ADHD Experts on Call' Program
... Deficit Hyperactivity
disorder (ADHD)
NEW YORK, Sept. 12 /PRNewswire/ -- The ... of patients with
Attention Deficit Hyperactivity
disorder (ADHD), as well as adults with
ADHD, with the ... for people to learn
about ADHD and how the
disorder impacts people of all ages," said David
Goodman, ...
CSL Behring's Innovative HeliTrax(SM) System Helps Physicians Manage Hemophilia A Patients
... technology to help those
living with a bleeding
disorder to manage their condition," said Garrett ... "CSL
Behring is committed to the bleeding
disorder community and continues to
develop creative ... Hemophilia
Hemophilia is an inherited bleeding
disorder characterized by prolonged
or spontaneous ...
Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.
... dimesylate) - Attention Deficit and
Hyperactivity
disorder ("ADHD")
- On April 23, 2008 Shire announced ... business on attention deficit and
hyperactivity
disorder (ADHD), human genetic therapies (HGT) ... dimesylate) (Attention Deficit and
Hyperactivity
disorder ("ADHD")); the impact of competitive ...
Shire Re-Launches ADHDSupport.com, a Virtual Road Map Providing Information, Tools and Practical Tips About Attention Deficit Hyperactivity Disorder (ADHD)
... resources about Attention Deficit Hyperactivity
disorder (ADHD). The
newly enhanced ADHDSupport.com ... daily
activities.
"ADHD is a common psychiatric
disorder that can impact the lives of
many people, ... and CEO of the national Attention Deficit
disorder Association
(ADDA), psychologist and consultant ...
Incorrectly cleaved protein leads to schizophrenia
... every year. The causes of this psychiatric
disorder are not yet clear. But now, VIB researchers ... is schizophrenia?
Schizophrenia is a mental
disorder that appears in about 1 out of every 250 ... how the person feels. Typical symptoms of the
disorder are: delusions, hallucinations, chaotic behavior, ...
Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
... of acute agitation in
schizophrenic or bipolar
disorder patients.
Mr. Kurtz was most recently Vice ... of acute
agitation in schizophrenic or bipolar
disorder patients, is in Phase 3
testing and has completed ... treatment of panic attacks associated
with panic
disorder are in Phase 2 testing. Product candidates in ...
FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
... most common
emotional, cognitive and behavioral
disorder treated in children(1), and
according to the ... on the life span of
the condition notes the
disorder impairs academic, social and ... the treatment of attention deficit
hyperactivity
disorder (ADHD) as part of a total treatment program that ...
Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
... clinical trial in patients with panic
disorder in April 2008. Alexza expects to report ... of acute
agitation in schizophrenic or bipolar
disorder patients, is in Phase 3
testing. AZ-001 (Staccato ... treatment of panic attacks associated
with panic
disorder are in Phase 2 testing. Product candidates in ...
Shire Launches Nationwide Adult ADHD Mobile Awareness Tour
... for adults
with Attention Deficit Hyperactivity
disorder (ADHD), a psychiatric
disorder that affects ... step toward recognizing the symptoms of the
disorder by answering the
6-question World Health ... Shire is partnering with the Attention
Deficit
disorder Association (ADDA), a leading adult ADHD patient ...
Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance
... VYVANSE(TM) - Attention Deficit and Hyperactivity
disorder ("ADHD")
- By April 11, 2008 VYVANSE had ... business on attention deficit and
hyperactivity
disorder (ADHD), human genetic therapies ... dimesylate) (Attention Deficit and
Hyperactivity
disorder ("ADHD")); the impact of competitive ...
FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
... the treatment of Attention Deficit
Hyperactivity
disorder (ADHD) in adults. VYVANSE, introduced in July ... people may think of ADHD as only a childhood
disorder but the
fact is that the majority of children ... and director of the
Adult Attention Deficit
disorder Center of Maryland. "The good news is that
in a ...
CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies
... will become the main supplier of bleeding
disorder treatments in
the province of Quebec.
CSL ... von Willebrand Disease
Hemophilia is a bleeding
disorder caused by a deficiency in one of the
blood ... hemophilia cases.
Hemophilia A is a hereditary
disorder in which the clotting ability of
the blood is ...
Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
... of acute agitation
in schizophrenic or bipolar
disorder patients.
"A key element of Alexza's ... of acute
agitation in schizophrenic or bipolar
disorder patients, is in Phase 3
testing. AZ-001 (Staccato ... treatment of panic attacks associated
with panic
disorder are in Phase 2 testing. Product candidates in ...
FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder
... to treat adult patients with major depressive
disorder (MDD). Wyeth
expects to begin shipping PRISTIQ to ... Major Depressive Disorder
Major depressive
disorder (MDD) is a common mental disorder, ... adults in short-term studies of major depressive
disorder (MDD) and other psychiatric disorders. -- ...
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
... for the treatment of major depressive
disorder (MDD) as
monotherapy, adjunct therapy, and ... adults in short-term studies of major
depressive
disorder and other psychiatric disorders. Patients of all ... in clinical trials for schizophrenia
and bipolar
disorder were dry mouth (9%-44% vs 3%-13%), sedation (30% ...
Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
... VYVANSE(TM) - Attention Deficit and Hyperactivity
disorder ("ADHD").
- Approved by the US Food and Drug ... business on attention deficit and
hyperactivity
disorder (ADHD), human genetic therapies ... dimesylate) (Attention Deficit and
Hyperactivity
disorder ("ADHD")); the impact of competitive ...
Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
... Hunter syndrome (MPS II) is a serious genetic
disorder mainly affecting
males that interferes with the ... business on attention deficit and
hyperactivity
disorder (ADHD), human genetic therapies ... on Shire's Attention Deficit and
Hyperactivity
disorder ("ADHD") franchise; patents, including but ...
Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder
... -- Patients with frequently
relapsing bipolar
disorder had a significant delay in the time to an
initial ... treatment
of frequently relapsing bipolar
disorder (FRBD). FRBD, defined as four or
more manic or ... "Patients with frequently relapsing bipolar
disorder require more
healthcare interventions than ...
FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
... strengths for the
attention deficit hyperactivity
disorder (ADHD) treatment, VYVANSE(TM)
(lisdexamfetamine ... in children and adolescents. The
disorder is also estimated to
affect 8.1 percent of ... U.S. adult population. ADHD is a neurobiological
disorder that
manifests as a persistent pattern of ...
Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
... pharmaceutical products for this
disorder and the current
treatment for Celiac is complete ... business on attention deficit and
hyperactivity
disorder (ADHD), human genetic therapies ... dimesylate) (Attention Deficit and
Hyperactivity
disorder ("ADHD")); the impact of competitive ...
New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
... of PRISTIQ for the
treatment of major depressive
disorder (MDD) experienced a statistically
significant ... and 100 mg in
Outpatients with Major Depressive
disorder in 2 Placebo-Controlled Trials
Data presented ... 5:30 p.m., Eastern U.S. Time.
"Major depressive
disorder is a chronic and disabling disease that can
cause ...
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
... (ADT) in adults with major depressive
disorder (MDD). ABILIFY is
the first medication approved ... this debilitating
illness." Major depressive
disorder affects millions of U.S. adults at some point
in ... with a primary diagnosis of major depressive
disorder who had
experienced an inadequate response to ...
Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
... with schizophrenia. Study overview: bipolar I
disorder (presented on Tuesday, 16 October at
12:00 p.m. ... mania associated
with bipolar I
disorder received either asenapine (5-10 mg twice ... School of Medicine in Wichita. About bipolar
disorder Bipolar disorder, commonly referred to as ...
Shire Divests Non-Core Product Portfolio to Almirall
... on building its
attention deficit hyperactivity
disorder (ADHD), human genetic therapies,
gastrointestinal ... business on attention deficit and
hyperactivity
disorder (ADHD), human genetic therapies ... on Shire's Attention Deficit and
Hyperactivity
disorder (ADHD) franchise; patents, including but not ...
Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
... Hunter syndrome (MPS II) is a serious genetic
disorder mainly affecting
males that interferes with the ... business on attention deficit and
hyperactivity
disorder (ADHD), human genetic therapies ... on Shire's Attention Deficit and
Hyperactivity
disorder ("ADHD") franchise; patents, including but ...
Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
... to primary care physicians and is the
most common
disorder diagnosed by gastroenterologists. Health care ... and maintenance treatment
of major depressive
disorder and for generalized anxiety
disorder in
adults; Namenda(R) (memantine HCl), an N- ...
Celebrity Designer Ty Pennington to Host 'ADHD Experts on Call' Program
... Deficit Hyperactivity
disorder (ADHD)
NEW YORK, Sept. 12 /PRNewswire/ -- The ... learn more about Attention Deficit
Hyperactivity
disorder (ADHD) from some of the nation's top ... business on attention deficit and
hyperactivity
disorder (ADHD), human genetic therapies ...
Enobia Pharma Raises $40.1 Million Series B Financing
... known cure for hypophosphatasia, a severe
genetic
disorder that affects the ability to mineralize bone. The ... proper bone mineralization.
The symptoms of the
disorder include: growth retardation, skeletal
deformities and frequent fractures. The
disorder is lethal in its most
severe form. Enobia is ...